CGEM vs TSHA: stock comparison and AI forecast
Cullinan Therapeutics, Inc. (CGEM) and Taysha Gene Therapies, Inc. (TSHA) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CGEM Cullinan Therapeutics, Inc.
- Price
- $15.75 +5.4% · 6M
- Market Cap
- $1.01B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
TSHA Taysha Gene Therapies, Inc.
- Price
- $4.00 -39.8% · 6M
- Market Cap
- $1.30B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- TSHA is 1.3 times larger than CGEM by market capitalization ($1.30B against $1.01B).
- Over the last six months CGEM returned +5.4% and TSHA -39.8%.
- TSHA carries 0.21 times debt per unit of equity, against 0.13 times for CGEM.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CGEM | TSHA |
|---|---|---|
| Market Cap | $1.01B | $1.30B |
| P/B Ratio | 3.15x | 3.37x |
| EPS | – | $-0.38 |
| Book Value/Share | $5.00 | $1.19 |
| Revenue/Share | – | $0.02 |
| FCF/Share | – | $-0.41 |
Profitability & Margins
| Metric | CGEM | TSHA |
|---|---|---|
| ROE | -63.6% | -38.6% |
| ROA | -56.3% | -31.8% |
| ROIC | -68.6% | -34.5% |
| Operating Margin | – | -2792.3% |
| Net Margin | – | -2728.0% |
| EBT Margin | – | -2792.3% |
| Tax Rate | 0.0% | 0.0% |
Financial Health
| Metric | CGEM | TSHA |
|---|---|---|
| Current Ratio | 8.42x | 17.76x |
| D/E Ratio | 0.13x | 0.21x |
| Financial Leverage | 1.13x | 1.21x |
| Interest Coverage | -1019.0x | -32.8x |
| Working Capital | $301M | $435M |
Cash Flow
| Metric | CGEM | TSHA |
|---|---|---|
| Operating Cash Flow | -$159M | -$132M |
| Free Cash Flow | – | -$133M |
| Capital Spending | – | -$380K |
| FCF/Sales | – | -2417.0% |
| CapEx/Sales | – | 7.0% |
Operational Efficiency
| Metric | CGEM | TSHA |
|---|---|---|
| Asset Turnover | – | 0.01x |
| Fixed Assets Turnover | – | 2.3x |
Income Statement
| Metric | CGEM | TSHA |
|---|---|---|
| Total Revenue | – | $5M |
| Operating Income | -$222M | -$153M |
| Net Income | -$205M | -$150M |
| R&D Expense | $171M | $123M |
Dividend & Shareholder Information
| Metric | CGEM | TSHA |
|---|---|---|
| Shares Outstanding | 64M | 326M |
CGEM vs TSHA: stock comparison and AI forecast
Which is bigger, CGEM or TSHA?
TSHA is 1.3 times larger than CGEM by market capitalization ($1.30B against $1.01B).
Which stock performed better over the last six months, CGEM or TSHA?
Over the last six months CGEM returned +5.4% and TSHA -39.8%.
Which one does Intratio's AI model rank higher, CGEM or TSHA?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.